CEO Richard Francis reflects on Teva’s return to growth during his tenure, and what’s next for the drugmaker in its quest to ...

They include a 3% WAC price increase implemented for Eli Lilly’s (NYSE ... such as AbbVie (ABBV), GSK (GSK), and Teva (TEVA), was subject to an FTC warning related to patent violations over ...

The FDA has approved Eli Lilly’s Emgality (galcanezumab ... unapproved therapies such as Botox and anti-seizure medication. Teva’s CGRP drug Ajovy (fremanezumab) was approved by the FDA ...

Eli Lilly said it expects to release data from a late-stage trial on its next-generation weight loss drug retatrutide in 2025, a few months earlier than expected. The company expects to provide ...

Eli Lilly And Co (NYSE:LLY) inked two strategic collaborations to expand radiopharmaceuticals and metabolic-associated ...